The clinical introduction of BRAF inhibitors (BRAFi), and later their combination with MEK inhibitors (MEKi), has substantially improved outcomes in patients with BRAF-mutant melanoma, outperforming previous chemotherapy-based treatments. This evidence concerns the gene MAP2K7 and melanoma.